Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review
Journal of Cardiovascular Pharmacology and Therapeutics · 2020-05 · 25 (3) · 201-211
DOI: 10.1177/1074248420902298 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, online erschienen am 06.02.2020. Verfasst von Sawsan AlMukdad und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, QU Health, Qatar University, Doha, Qatar. Hauptthemen laut MEDLINE: Drug Costs, Pharmacogenomic Variants. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Qatar University.
Abstract (Originalsprache)
Background and Objectives: Clopidogrel is widely used after the percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) and requires activation by cytochrome P450 (CYP), primarily CYP2C19. Patients with CYP2C19 loss-of-function alleles are at increased risk of major adverse cardiovascular events, while more expensive novel antiplatelet agents (ticagrelor and prasugrel) are unaffected by the CYP2C19 mutations. This systematic review aims to answer the question about whether overall evidence supports the genotype-guided selection of antiplatelet therapy as a cost-effective strategy in post-PCI ACS.
Methods
A systematic literature search of PubMed, EMBASE, EconLit, and PharmGKB was done to identify all the economic evaluations related to genotype-guided therapy compared to the universal use of antiplatelets in ACS patients. Quality of Health Economic Studies tool was used for quality assessment.
Results
The search identified 13 articles, where genotype-guided treatment was compared to universal clopidogrel, ticagrelor, and/or prasugrel. Six studies showed that genotype-guided therapy was cost-effective compared to universal clopidogrel, while 5 studies showed that it was dominant. One study specified that genotype-guided with ticagrelor is cost-effective only in both CYP2C19 intermediate and poor metabolizers. Genotype-guided therapy was dominant when compared to universal prasugrel, ticagrelor, or both in 5, 1, and 3 studies, respectively. Only 2 studies reported that universal ticagrelor was cost-effective compared to genotype-guided treatment. All the included articles had good quality.
Conclusion
Based on current economic evaluations in the literature, implementing CYP2C19 genotype-guided therapy is a cost-effective approach in guiding the selection of medication in patients with ACS undergoing PCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
ORCID-Profile: Sawsan AlMukdad, Daoud Al-Badriyeh
Förderung
- Qatar University
Zitieren
APA
AlMukdad, S., Elewa, H., & Al-Badriyeh, D. (2020). Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics, 25(3), 201-211. https://doi.org/10.1177/1074248420902298
Vancouver
AlMukdad S, Elewa H, Al-Badriyeh D. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics. 2020;25(3):201-211. doi:10.1177/1074248420902298
BibTeX
@article{AlMukdad2020,
author = {AlMukdad, Sawsan and Elewa, Hazem and Al-Badriyeh, Daoud},
title = {Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review},
journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
year = {2020},
volume = {25},
number = {3},
pages = {201--211},
doi = {10.1177/1074248420902298}
}
EUVIMED